In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...
Vutrisiran treatment reduced the risk of death and recurrent cardiovascular events compared to placebo in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results